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metropolitan area of Kumasi, Ghana, with randomly selected 500 mothers and
caregivers, interviewed with questionnaire administration in their homes and in
the health facilities. The study was conducted from May – September, 2010. The
study had ethical clearance. Informed consenting processes were strictly followed.
Data was analysed using descriptive statistics and logistic regression to examine
the predictors of appropriate use of ITNs among children under five years at 95%
confidence interval. Data was analysed into descriptive statistics using the Statis-
tical STATA version 11 software. RESULTS: The study found that 50% of the par-
ticipants owned ITNs, and of this only 67% used it the night before the study.
Meanwhile, 21% of those who owned the nets used them occasionally. Also 39% of
the total population did not own any ITN at all. The predictors of appropriate use of
ITNs were found to be income levels, health seeking behaviour of caregivers and
the room structure of participants. CONCLUSIONS: Appropriate ITN use in the
study area is determined by incomes of participants, room structures, and health
seeking behaviour of users. A comparative study between urban and rural commu-
nities could be useful for nationwide intervention to improve current situation.
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ANALISIS COSTO EFECTIVIDAD SECTORIAL DE 45 INTERVENCIONES
SANITARIAS EN CHILE
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OBJECTIVOS: Apoyar la priorización de problemas de salud a ser incorporados en
las Garantías Explicitas en Salud, a partir del análisis costo-efectividad de 45 inter-
venciones destinadas a reducir la mortalidad o discapacidad. METODOLOGÍAS:
Análisis Costo-Efectividad Sectorial. Se definieron los procesos productivos para
cada intervención (diagnóstico, tratamiento y seguimiento). Se costearon 309
prestaciones, en base a una muestra de establecimientos públicos. Los costos están
expresados en moneda chilena a Junio 2009. La eficacia de cada intervención se
determinó por revisión sistemática. Se construyó un modelo de historia natural
(sin intervención) para cada enfermedad, y se contrastó con un modelo que incor-
pora la intervención. El resultado de eficacia obtenido se ponderó por adherencia,
cumplimiento de prestadores, y cobertura, obteniendo así el indicador de efectivi-
dad por caso incidente tratado. Los resultados de efectividad se expresan en Dis-
ability Adjusted Life Years (DALY) evitados. Se aplica tasa de descuento (6%) para
costos y resultados. El horizonte temporal se define por la expectativa de vida
mediana para la cohorte de pacientes. RESULTADOS: Se obtiene la razón costo-
efectividad de cada intervención, y se construye un ranking de costo-efectividad,
identificando aquellas muy costo-efectivas, potencialmente costo-efectivas, y no
costo-efectivas. Se propone un umbral de pago por DALY evitado: una intervención
es muy costo-efectiva si previene 1 DALY a costo igual o inferior a 1 PIB (producto
interno bruto) per cápita: potencialmente costo-efectiva si previene 1 DALY a un
costo entre 1 y 3 PIB per cápita; y no costo-efectiva si el resultado es mayor.
CONCLUSIONES: Se proporciona una metodología y resultados concretos que
apoyan el proceso de toma de decisiones sanitarias en Chile. Al día de hoy, varias
de las intervenciones costo-efectivas han sido incorporadas a la Ley de Garantías
Explícitas. Se sugiere un umbral de pago por DALY evitado en el país para futuras
decisiones.
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LINEAMIENTOS DE UNA POLÍTICA DE INVESTIGACIÓN EN SALUD EN CHILE:
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EL PLAN NACIONAL DE SALUD 2011-2020
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Delgado M3, Ramirez J3
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OBJECTIVOS: Chile ha avanzado en el desarrollo de investigación en salud (IS). Sin
embargo, aún falta definir un marco conceptual que de soporte a una política de IS
de largo plazo. El nuevo Plan Nacional de Salud 2011-2020 (PNS) ha incluido, por
primera vez, como objetivo el desarrollo de IS en Chile. El presente reporte presenta
los lineamientos directrices de la política de IS en Chile para el nuevo PNS.
METODOLOGÍAS: El Ministerio de Salud convocó a un sub-comité de profesionales
vinculados a salud para desarrollar aspectos a considerar en una política de IS. Se
realizó una revisión de situación de IS en Chile, identificando elementos teóricos y
empíricos centrales para fortalecer su desarrollo. A partir de múltiples encuentros
de discusión temática, se definieron metas de IS al año 2020 y estrategias para su
cumplimiento. RESULTADOS: El comité definió los siguientes cinco lineamientos:
1) La inversión en IS-aplicada debe ser consistente con objetivos de salud definidos
por PNS; 2) IS se justifica desde el presupuesto de salud si permite resolver incerti-
dumbre de la autoridad sanitaria, reduciendo el costo-esperado de decisiones in-
correctas; 3) Se adopta el marco teórico de investigación traslacional que incluye
distintos niveles/tipos de IS, alineados con necesidades/prioridades de la autori-
dad; 4) Se deben explicitar los tópicos de IS y establecer mecanismos transparentes
para su priorización (priority-setting-methodology); dichos tópicos deben articu-
larse con la evaluación de nuevas intervenciones y considerar la colaboración con
sociedades-científicas; (5) Se debe potenciar la vinculación pública-académica-pri-
vada en la ejecución y financiamiento de proyectos. A partir de estos lineamientos,
se definieron las metas y estrategias para IS en PNS, conforme a necesidades,
restricciones y desafíos actuales del país. CONCLUSIONES: Este reporte destaca las
bases conceptuales y lineamientos del desarrollo de una política de IS en Chile. Las
metas y estrategias para el nuevo PNS son definidas a partir de esta iniciativa.
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KNOWLEDGE, ATTITUDE, AND PRACTICES (KAP) OF FOOD PRACTITIONERS ON
HAZARD ANALYSIS AND CRITICAL CONTROL POINT (HACCP) IN THE KUMASI
METROPOLIS, GHANA
Agyei-Baffour P, Boateng K, Nakua E, Otupiri E, Owusu-Dabo E
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OBJECTIVES: To assess knowledge, attitude, and practices (KAP) of food practitio-
ners on hazard analysis and critical control point (HACCP) in the Kumasi Metrop-
olis, Ashanti, METHODS: A descriptive cross sectional survey with randomly se-
lected 450 food practitioners and 50 key informants was conducted from May –
September 2009. Data collection was done with the use of questionnaire and inter-
view guide administered by university trained research assistants. Data was ana-
lysed into descriptive statistics using the Statistical Package for Social Sciences
(SPSS) version 15.0. The data analysis was done at 95% confidence interval with
significance level 0.05 or less and at 95% confidence interval. The study had ethical
clearance and Informed consent was sought from respondents. RESULTS: The
knowledge level of food practitioners on HACCP was extremely low, only 25% knew
it. HACCP has not been widely used, less than one third, 24%, of food practitioners’
use it. Little use of HACCP has negative impact on the general knowledge level and
food handling practices of food practitioners, p0.031. Majority have not even
heard about it and therefore shows no positive signs of adherence and effort to
practice. More than 85% of the respondents did not attend any educational course
on food hygiene and food borne disease. CONCLUSIONS: There is poor knowledge
on hazard analysis and critical control point among food services staff. Studies
involving the use of both qualitative and quantitative research methods and envi-
ronmental exposures will be helpful to design interventions to improve food hy-
giene.
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NECESIDADES DE INFORMACIÓN Y FORMACIÓN SOBRE FARMACOECONOMIA E
INVESTIGACIÓN DE RESULTADOS PARA PROFESIONALES Y ESTUDIANTES DE
FARMACIA DEL ORIENTE VENEZOLANO
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OBJECTIVOS: Describir la necesidades sobre información y formación en Farmaco-
economia e Investigaciones de Resultados de profesionales y estudiantes de
Farmacia asentados en el oriente de Venezuela. METODOLOGÍAS: Estudio descrip-
tivo transversal realizado a la población asistente de la 14a reunión anual de la
Federación Farmacéutica de Venezuela celebrada en el estado Anzoátegui en el
mes de marzo de 2011, mediante el cuestionario desarrollado por los Consorcios de
Asia y America Latina de ISPOR y, disponible en la pagina web de ISPOR para
evaluar la necesidad para la investigación de farmacoeconomia e investigación de
resultados. RESULTADOS: Del total de encuestados (N: 74), el 53% son profesion-
ales farmacéuticos en ejercicio y el resto estudiantes de Farmacia del núcleo de
oriente de la Universidad Santa Maria. La mayoría de los profesionales (66%) trabaja
en establecimientos de Farmacia para la comunidad. El 83% de los encuestados
señala no haber recibido actividades educativas o de formación en Farmacoecono-
mia e Investigación de Resultados. El análisis de costos y los estudios de costo
beneficio concentran los métodos percibidos que usualmente se utilizan (41%). Un
56% de los encuestados considera que las autoridades no toma en cuenta los re-
sultados de los estudios llevados a cabo, y un 59% se preocupa por la falta de
conocimiento de los temas farmacoeconomicos en el país. Así mismo, 91% quisiera
más formación educativa y aplicaciones prácticas de la disciplina. El 77% nunca ha
escuchado de la existencia de ISPOR, y un 55% de los mismos estarían interesados
en ser miembros del capitulo local del ISPOR. CONCLUSIONES: Los resultados de
este estudio sugieren la necesidad de que ISPOR Venezuela siga profundizando los
esfuerzos para promover la farmacoeconomia y la investigación de resultados en
Venezuela y, específicamente, con los Farmacéuticos y estudiantes de Farmacia de
la zona oriental del país.
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PERCEPTIONS, KNOWLEDGE AND GAPS ABOUT HTA AND HEALTH ECONOMICS
BY THE BRAZIIAN MARKET STAKEHOLDERS: ISPOR BRAZIL QUALITATIVE
RESEARCH
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OBJECTIVES:Understand the Brazilian set needs about HTA and Health economics.
METHODS: In deep interview, based on a structured questionnaire, with decision
makers from the public and private set, Prescriptors, Patients group and
Manufacturers. RESULTS: A total of 131 interviews was conducted: 60 decision
makers, 50 Prescriptors, 10 patients groups and 11 manufacturers. For the decision
makers and Manufacturers, HTA and Health economics its’ a main issue and, de-
spite several methodological mistakes, takes an important role on the decision and
business. Patient groups and prescirptors are not very well awarned about the
issues in analysis, but consider that a better knowledge about is important and can
be very useful for the prescriptor and patients. For all the stakeholders, education
and access to clear information was a main issue of need. CONCLUSIONS: Consid-
ering the rich database that this research provides and the knowledge about the
needs and points to enforce, ISPOR Brazil will be able to act with more focus.
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OBJECTIVES: Although HTA is well established in healthcare systems like the Eng-
land & Wales National Health Service (NHS), it is increasingly used more formally
in developing countries such as Poland and Mexico. The objectives of this research
were to understand the drivers of decision-making and future trends in these HTA
systems in relation to market access for pharmaceuticals. METHODS: Secondary
research and structured telephone interviews with 12 key stakeholders in Poland
and Mexico was carried out. The research evaluated trends in the following aspects
of the systems: impact of HTA in final reimbursement decisions, positioning of HTA
in the healthcare system and future trends. A comparison of the impact of HTA in
Mexico and Poland was then made on a rating scale devised to account for these
influencing factors. RESULTS: HTA in Mexico is positioned within a highly decen-
tralised healthcare system, although its Federal Cuadro Básico is important in
determining price and access for pharmaceuticals. HTA appraisals although
mostly conducted by IMSS (60% of reimbursement) are also used by the other
reimbursing institutions. The Polish HTA body, AHTAPol, works closely with the
reimbursement process at the central level, but its ultimate influence on price and
reimbursement is moderate; the majority of respondents (n8) regarded HTA as
more of a negotiating tool, as decision-making balances multiple diverse interests.
CONCLUSIONS: HTA is seen to impact the Polish system, despite being centralised
to a lesser extent than Mexico, which has a decentralised health system and a
significant private sector. In addition to HTA, historical development of the health
care system, external influences and financial resources are equally important
drivers of access decisions.
PHP37
CROSS-CONTINENTAL COMPARISON OF HTA EVOLUTION IN EMERGING
MARKETS: BRAZIL, INDIA AND POLAND
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OBJECTIVES: Despite universal healthcare being the common motto, healthcare
systems in developing economies around the world have developed to varying
extents. HTA as a concept has evolved particularly in Western European markets to
ensure equity and equality of healthcare provision. Understanding the status of
HTA evolution and impact on reimbursement decisions is expected to have lessons
to be learnt for countries like India where non-evolution of HTA is seen.METHODS:
Secondary research to understand the reimbursement systems publicly available
information about recent reimbursement decisions was done. Primary research
involved discussions with decision makers in important reimbursement bodies.
Eight in-depth interviews were conducted covering individuals from a variety of
backgrounds. Information was collected under headings covering current drivers,
historical influences, existing issues, reasons for evolution / non-evolution of HTA
and expected changes. Data was analysed qualitatively to develop results.
RESULTS: Broadly, HTA was seen to be non-evolved in India. Majority of the market
being out-of-pocket is considered the key driver where both industry and doctors
are thought to generally oppose any formal technology appraisals (n6). At the
other end of the spectrum, despite having a multi-payer reimbursement system,
Brazil was seen to be using HTA as a tool for reimbursement decisions widely (n6).
Poland however, despite having a well-developed HTA system was seen to use HTA
more as a negotiation tool than for reimbursement decisions (n4).
CONCLUSIONS: A tri-directional comparison of HTA systems and their involve-
ment in the reimbursement system showed that the reasons behind the varying
level of HTA influence can be attributed somewhat to the history of the healthcare
systems. There are lessons to be learned for Poland, which is a centralised system
from other centralised systems like England and for India from Brazil. In-depth
research involving lessons from Brazil for India is warranted.
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HEALTH TECHNOLOGY ASSESSMENT APPLIED TO MEDICAL DEVICES IN LATIN
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OBJECTIVES: Analyze the health technology assessment (HTA) scenario and pro-
cess to Medical Devices (MD) in Latin American and discuss the appropriateness of
the present process. METHODS: search in Latin American and Caribbean Health
Sciences Literature (LILACS), PubMed, gray literature and internet search.
RESULTS:MD and drugs differ from their concept to usage, therefore it is important
to note that is not always possible to apply the same HTA processes to both cate-
gories. In the research, we found in Latin America 12 countries with significant HTA
initiatives and the majority emerged in the past decade. In total, 4 countries with
published economic evaluation guidelines, 17 HTA committees and groups, 6 IS-
POR chapters, the Pan American Health Organization (PAHO) HTA initiative and
Mercosur HT special group. The expertise with HTA applied to drugs seems to be
higher than HTA applied to MD across Latin America and this was observed in
appraisals published by the main HTA agencies. Important to note the almost non
existence of specific HTA guidelines to MD among HTA agencies, groups and
committees. CONCLUSIONS: The methodological validity should consider a
broader source of evidence to evaluate the efficacy of certain MD or for certain
clinical indications or settings. Patient and/or investigator blinding is impractical
or impossible for many MD and most surgical procedures. Observational studies
should be considered as a relevant source of data for HTA, often randomized clin-
ical trials do not provide real life data and are not always feasible technically and
ethically for devices. MD has a shorter life cycle and it is not compatible with HTA
cycles which can vary from 6 months to 4 years for a sound assessment. HTA
agencies, committees and groups in Latin America must recognize the medical
devices specificities and its market dynamics and incorporate to existing guide-
lines a process adequate to this category.
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FIVE MARKETS IN LATIN AMERICA
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OBJECTIVES: HTA is at different stages of development across Latin America, from
Brazil’s highly developed system at one extreme to Venezuela at the other, despite
the existence of substantial local expertise. This study attempts to explain these
disparities. METHODS: A total of 20 HTA reviewers and academic health econo-
mists were interviewed across Brazil, Argentina, Mexico, Chile and Venezuela to
understand the parameters of the HTA system, the importance of different stake-
holders within the process and the decisions influenced by HTA. RESULTS: HTA
systems within Latin America exist at all stages of the HTA development contin-
uum, although they are better developed than in many other developing countries.
At one end sits a multi-payer, universal health system Brazil in which demonstra-
tion of cost-effectiveness is considered highly important for central funding deci-
sions. At the other extreme sit Chile and Venezuela in which no formal role for HTA
yet exists, although the speed and direction of HTA development in these two
countries is likely to differ. In between sits Argentina, where HTA capability is
advanced but operating within a fragmented health system. CONCLUSIONS: HTA
is developing rapidly within the markets surveyed suggesting that private actors
would be rational to invest in local expertise. However, despite formalisation, cost-
effectiveness may remain only one of many decision factors. Understanding the
nuances of where HTA sits in the reimbursement system and how it is applied in
practice in each market is essential for maximising favourable outcomes for sup-
pliers and providers alike.
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PROMOTING EFFICIENCY OF AVAILABLE CAPACITY IN A FRAGMENTED
HEALTH SYSTEM: PATIENTS WITH DIFFERENT HEALTH INSURANCE SCHEMES
ATTENDED BY MOH, MEXICO 2006-2010
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OBJECTIVES: In order to implement strategies that promote an efficient use of
public health services and grant more access opportunities to the population, irre-
spective of their insurance status, estimate the volume and type of hospital care
services provided by the Ministry of Health (MoH) to patients who have social
security or private health insurance. METHODS: The exercise was made though an
analysis by ICD-10 of the Hospital Discharge Automated System, which concen-
trates hospital activity from over 600 hospitals belonging to MoH, between January
2006 and August 2010. Patients having a social security scheme (IMSS, ISSSTE,
PEMEX, SEDENA y SEMAR) or private health insurance were analyzed. RESULTS: A
total of 11.9 million of attentions were recorded in the analyzed period, 2.2 on
average per year, of which, 40 thousand (1.7%) corresponded to patients who be-
long to a social security institution or private health insurance. Among the insti-
tutions of origin, IMSS led the list with 45% of the total, followed by ISSSTE with 26%
and private insurances with 20%. By ICD-10 chapter, Pregnancy, childbirth and puer-
perium (O00-O99) was the most demanded, with 24.5% of the total attentions. In the
analysis by state, about 50% of cases came from five to seven states; in 2010 the
state of Jalisco led the list with 14.5% of the total, followed by the states of Tama-
ulipas and Mexico, with about 7% each. Considering all the analyzed period, the
most common intervention was Single spontaneous delivery (O80), (41% in 2010).
CONCLUSIONS: Quantifying the MoH health care demand coming from social and
private insured population and its evolution will permit the definition of better
exchange planning strategies and guarantee its appropriate financial compensa-
tion. Besides analyze the exchange volume and their characteristics; establishing
fees and agreements is needed to implement reimbursement systems between
public sector institutions.
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MONITORING OF HPV VACCINATION EFFECTIVENESS WITHIN EUROPEAN
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OBJECTIVES: The study evaluated recent data related to real impact measurement
of HPV prevention or cervical oncologic diseases related to HPV infection available
from publications in the EU member states. The main idea was to find out whether
there is any prerequisite to evaluate the effectiveness of the preventive HPV vac-
cination based on the existing data and standard approaches within the EU in the
future in an observational study. The second goal was to define these prerequisites
in order to use them for “good practice.” METHODS: The systematic review of
PUBMED, EMBASE and CENTRAL extended to official websites of public health in-
stitutions officially published data was used. The goal was to find all papers on
HPV/cervical cancer epidemiology, screening, and prevention published in years
2009- 2011, related to EU member states. Only studies related to countries from the
European Union were taken into account. All relevant data were extracted and
compared. Population size was derived from Eurostat. Based on this data we cre-
ated the principles for evaluation of HPV screening and monitoring of quality
indicators. RESULTS:Out of 27 EU countries, only 2 countries (Denmark and United
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